Literature DB >> 9032383

A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE.

E Buratti1, S G Tisminetzky, P D'Agaro, F E Baralle.   

Abstract

We report here that a human immunodeficiency virus type 1 (HIV-1)-specific neutralizing monoclonal antibody (MAb 1575) mapped to the conserved putative intracellular region from amino acid residues 735 to 752 (735-752 region) of gp41 also recognizes a region in an extracellular portion of p17. Both epitopes have a core recognition sequence (IEEE) in a nonhomologous context. The IEEE motif found in HIV-1 p17 is located in a region known as HGP-30 (residues 86 to 115) which has been previously associated with virus neutralization, cytotoxic T lymphocyte activity, and mother-to-child transmission. An analysis of available gp41 and p17 sequences demonstrates that in these regions both IEEE sequences are highly conserved in different HIV-1 clades. The presence of the IEEE epitope in p17 allows us to explain some unexpected neutralizing characteristics of MAb 1575. In addition, the gp41 735-752 region has been previously reported both in intra- and extracellular locations. Our results suggest that the extracellular location was the result of cross-reactivity with p17.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032383      PMCID: PMC191356     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  A blocking agent and a blocking step are not needed in ELISA, immunostaining dot-blots and western blots.

Authors:  K Mohammad; A Esen
Journal:  J Immunol Methods       Date:  1989-02-08       Impact factor: 2.303

2.  Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping.

Authors:  L D Papsidero; M Sheu; F W Ruscetti
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

3.  Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide.

Authors:  A G Dalgleish; T C Chanh; R C Kennedy; P Kanda; P R Clapham; R A Weiss
Journal:  Virology       Date:  1988-07       Impact factor: 3.616

4.  Conformational display of two neutralizing epitopes of HIV-1 gp41 on the Flock House virus capsid protein.

Authors:  E Buratti; S G Tisminetzky; E S Scodeller; F E Baralle
Journal:  J Immunol Methods       Date:  1996-10-16       Impact factor: 2.303

5.  The immunodominance of epitopes within the transmembrane protein (gp41) of human immunodeficiency virus type 1 may be determined by the host's previous exposure to similar epitopes on unrelated antigens.

Authors:  D Davis; B Chaudhri; D M Stephens; C A Carne; C Willers; P J Lachmann
Journal:  J Gen Virol       Date:  1990-09       Impact factor: 3.891

6.  Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30.

Authors:  C A Boucher; W J Krone; J Goudsmit; R H Meloen; P H Naylor; A L Goldstein; D K Sun; P S Sarin
Journal:  J Clin Lab Anal       Date:  1990       Impact factor: 2.352

7.  HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals.

Authors:  A Achour; O Picard; D Zagury; P S Sarin; R C Gallo; P H Naylor; A L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

8.  Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.

Authors:  D D Ho; J A McKeating; X L Li; T Moudgil; E S Daar; N C Sun; J E Robinson
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies.

Authors:  D J Evans; J McKeating; J M Meredith; K L Burke; K Katrak; A John; M Ferguson; P D Minor; R A Weiss; J W Almond
Journal:  Nature       Date:  1989-06-01       Impact factor: 49.962

10.  Induction of anti-HIV neutralizing antibodies by synthetic peptides.

Authors:  T C Chanh; G R Dreesman; P Kanda; G P Linette; J T Sparrow; D D Ho; R C Kennedy
Journal:  EMBO J       Date:  1986-11       Impact factor: 11.598

View more
  9 in total

1.  HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor.

Authors:  Maria A De Francesco; Manuela Baronio; Simona Fiorentini; Costantino Signorini; Carlo Bonfanti; Claudio Poiesi; Mikulas Popovic; Manuela Grassi; Emirena Garrafa; Luisa Bozzo; George K Lewis; Stefano Licenziati; Robert C Gallo; Arnaldo Caruso
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-08       Impact factor: 11.205

2.  Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.

Authors:  N M Stamatos; J R Mascola; V S Kalyanaraman; M K Louder; L M Frampton; D L Birx; T C VanCott
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

3.  Identification of a protective CD4+ T-cell epitope in p15gag of Friend murine leukemia virus and role of the MA protein targeting the plasma membrane in immunogenicity.

Authors:  Daisuke Sugahara; Sachiyo Tsuji-Kawahara; Masaaki Miyazawa
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

4.  Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone.

Authors:  Agnès-Laurence Chenine; Lindsay Wieczorek; Eric Sanders-Buell; Maggie Wesberry; Teresa Towle; Devin M Pillis; Sebastian Molnar; Robert McLinden; Tara Edmonds; Ivan Hirsch; Robert O'Connell; Francine E McCutchan; David C Montefiori; Christina Ochsenbauer; John C Kappes; Jerome H Kim; Victoria R Polonis; Sodsai Tovanabutra
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

5.  Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo.

Authors:  Bernard Verrier; Stéphane Paul; Céline Terrat; Liza Bastide; Agathe Ensinas; Capucine Phelip; Blandine Chanut; Laura Bulens-Grassigny; Fabienne Jospin; Christophe Guillon
Journal:  Front Immunol       Date:  2017-06-30       Impact factor: 7.561

6.  Phage-displayed peptides having antigenic similarities with porcine epidemic diarrhea virus (PEDV) neutralizing epitopes.

Authors:  Deu John M Cruz; Chul-Joong Kim; Hyun-Jin Shin
Journal:  Virology       Date:  2006-09-01       Impact factor: 3.616

7.  The GPRLQPY motif located at the carboxy-terminal of the spike protein induces antibodies that neutralize Porcine epidemic diarrhea virus.

Authors:  Deu John M Cruz; Chul-Joong Kim; Hyun-Jin Shin
Journal:  Virus Res       Date:  2007-12-11       Impact factor: 3.303

8.  The Carboxy Terminal Region on Spike Protein of Porcine Epidemic Diarrhea Virus (PEDV) Is Important for Evaluating Neutralizing Activity.

Authors:  Ki-Jong Kang; Dong-Hwan Kim; Eui-Ju Hong; Hyun-Jin Shin
Journal:  Pathogens       Date:  2021-05-31

Review 9.  C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic.

Authors:  Jonathan D Steckbeck; Anne-Sophie Kuhlmann; Ronald C Montelaro
Journal:  J Gen Virol       Date:  2012-10-17       Impact factor: 3.891

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.